Drug-drug, drug-dietary supplement, and drug-citrus fruit and other food interactions: What have we learned?

Journal of Clinical Pharmacology

Volumn 44, Issue 6, 2004, Pages 559-569

  Huang, Shiew Mei ^a   Lesko, Lawrence J ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Drug development; Drug dietary supplement interaction; Drug drug interaction; Drug juice interaction; Exposure response relationship; Labeling; Risk management

Indexed keywords

ALOSETRON; ASTEMIZOLE; BROMFENAC; CAFFEINE; CERIVASTATIN; CISAPRIDE; CYCLOSPORIN; CYCLOSPORIN A; DEXTROMETHORPHAN; ETHINYLESTRADIOL PLUS ETONOGESTREL; GREPAFLOXACIN; HYPERICUM PERFORATUM EXTRACT; IMATINIB; LOPINAVIR; MIBEFRADIL; MIDAZOLAM; MIFEPRISTONE; NEW DRUG; ORAL CONTRACEPTIVE AGENT; RAPACURONIUM BROMIDE; RAPAMYCIN; RIFABUTIN; RIFAMPICIN; RITONAVIR; ROSUVASTATIN; SELDANE D; SEROTONIN UPTAKE INHIBITOR; SILDENAFIL; TERFENADINE; TOLBUTAMIDE; TROGLITAZONE; UNINDEXED DRUG;

APPLE JUICE; AREA UNDER THE CURVE; BREAKTHROUGH BLEEDING; BRONCHOSPASM; CITRUS FRUIT; CONSTIPATION; CRANBERRY; DIET SUPPLEMENTATION; DOSE RESPONSE; DRUG ANTAGONISM; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DEVELOPMENT; DRUG DIETARY SUPPLEMENT INTERACTION; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG JUICE INTERACTION; DRUG LABELING; DRUG MARKETING; DRUG MECHANISM; DRUG RESEARCH; DRUG WITHDRAWAL; FOOD DRUG INTERACTION; GENDER; GRAPEFRUIT JUICE; HEALTH CARE PERSONNEL; HUMAN; ISCHEMIC COLITIS; LIVER FAILURE; ORANGE JUICE; PATIENT INFORMATION; PHARMACODYNAMICS; PHARMACOGENETICS; PHARMACOKINETICS; REVIEW; RHABDOMYOLYSIS; RISK MANAGEMENT; TORSADE DES POINTES;

BEVERAGES; CITRUS; DIETARY SUPPLEMENTS; DRUG INTERACTIONS; DRUG LABELING; FEMALE; FOOD-DRUG INTERACTIONS; HERB-DRUG INTERACTIONS; HUMANS; MALE; PHARMACOGENETICS; SEX FACTORS;

EID: 2442700486     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270004265367     Document Type: Review

References (78)

1. Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA: Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA 2002;287:337-344.
2. Richardson MA, Ramirez T, Palmer JL, Greisinger A, Singletary SE: Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol 2000;18:2505-2514.
3. Sparber A, Wootton JC, Bauer L, Curt G, Eisenberg D, Levin T, et al: Use of complementary medicine by adult patients participating in HIV/AIDS clinical trials. J Altern Complement Med 2000;6(5):415-422.
4. Huang S-M, Lesko LJ, Williams RL: Assessment of the quality and quantity of drug-drug interaction studies in NDA submissions: study design and data analysis issues. J Clin Pharmacol 1999;39:1006-1014.
5. Davit B, Reynolds K; Yuan R, Ajayi F, Conner D, Fadiran E, et al: FDA evaluations using in vitro metabolism to predict and interpret in vivo metabolic drug-drug interactions: impact on labeling. J Clin Pharmacol 1999;39(9):899-910.
6. Marroum PJ, Uppoor RS, Parmelee T, Ajayi F, Burnett A, Yuan R, et al: In vivo drug-drug interaction studies-a survey of all new molecular entities approved from 1987 to 1997. Clin Pharmacol Ther 2000;68(3):280-285.
7. Yuan R, Madani S, Wei XX, Reynolds K, Huang SM: Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. Drug Metab Dispos 2002;30(12):1311-1319.
8. Prueksaritanont T, Zhao JJ, Ma B, Roadcap BA, Tang C, Qiu Y, et al: Mechanistic studies on metabolic interactions between gemfibrozil and statins. Pharmacol Exp Ther 2002;301(3):1042-1051.
9. Mizuno N, Niwa T, Yotsumoto Y, Sugiyama Y: Impact of drug transporter studies on drug discovery and development. Pharmacol Rev 2003;55:425-461.
10. Lin JH: Drug-drug interaction mediated by inhibition and induction of P-glycoprotein. Adv Drug Deliv Rev 2003;55(1):53-81.
11. Lin JH, Yamazaki M: Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet 2003;42(1):59-98.
12. Dresser GK, Bailey DG, Leake BF, Schwarz UI, Dawson PA, Freeman DJ, et al: Fruit juices inhibit organic anion transporting polypeptide-mediated uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther 2002;71:11-20.
13. Food and Drug Administration: Guidance for Industry: Drug Metabolism/ Drug Interactions in the Drug Development Process: Studies In Vitro. Rockville, MD: Food and Drug Administration, 1997. Retrieved from www.fda.gov/cder
14. Food and Drug Administration: Guidance for Industry: In Vivo Metabolism/Drug Interactions: Study Design, Data Analysis and Recommendation for Dosing and Labeling. Rockville, MD: Food and Drug Administration, 1999. Retrieved from www.fda.gov/cder
15. Food and Drug Administration: Issues and challenges in the evaluation and labeling of drug interaction potentials of NME. Paper presented at the Food and Drug Administration Advisory Committee for Pharmaceutical Sciences and Clinical Pharmacology Subcommittee meeting, Rockville, MD, April 23, 2003. Retrieved from www.fda.gov/ohrms/dockets/ac/03/slides/3947s2.htm; www.fda.gov/ohrms/dockets/ac/03/transcripts/3947T2.htm
16. Food and Drug Administration: CYP2C8 and CYP2B6-based drug interaction. Paper presented at the Food and Drug Administration Advisory Committee for Pharmaceutical Sciences and Clinical Pharmacology Subcommittee meeting, Rockville, MD, November 18, 2003. Retrieved from www.fda.gov/ohrms/dockets
17. Labeling guideline. Fed Reg 2000;65(247):81082-81131.
18. Tucker T, Houston JB, Huang S-M: Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential - toward a consensus. Clin Pharmacol Ther 2001;70:103.
19. Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, et al: The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 2003;31(7):815-832.
20. Food and Drug Administration: Guidancefor Industry: Exposure-Response Relationship, Study Design, Data Analysis, and Regulatory Applications. Rockville, MD: Food and Drug Administration, 2003. Retrieved from www.fda.gov/cder
21. Blasetto J: Crestor® clinical development efficacy. Paper presented at the Endocrine and Metabolic Drugs Advisory Committee meeting, Gaithersburg, MD, July 9, 2003. Retrieved from cdernet.cder.fda.gov/ACS/index.html
22. Lubas L: Crestor® safety and dosing. Paper presented at the Endocrine and Metabolic Drugs Advisory Committee meeting, Gaithersburg, MD, July 9, 2003. Retrieved from cdernet.cder.fda.gov/ACS/index.html
23. Crestor® approved labeling. Retrieved from www.fda.gov/cder/approval/index.htm
24. Levitra® approved labeling. Retrieved from www.fda.gov/cder/approval/index.htm
25. Tesch BJ: Herbs commonly used by women: an evidence-based review. Am J Obstet Gynecol 2003;188(suppl 5):S44-S55.
26. Moore LB, Goodwin B, Jones SA, et al: St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci USA 2000;97:7500-7502.
27. Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J: Indinavir concentrations and St John's wort. Lancet 2000;355:547-548
28. Ruschitzka F, Meier PJ, Turina M, Luscher TF, Noll G: Acute heart transplant rejection due to Saint John's wort [letter] [see comments]. Lancet 2000;355:548-549.
29. FDA public health advisory: risk of drug interactions with St John's wort and indinavir and other drugs. Retrieved from www.fda.gov/cder/drug/advisory/stjwort.htm
30. Chen MC, Huang S-M, Mozersky R, Beitz J, Honig P: Drug interactions involving St. John's wort: data from FDA's adverse reaction reporting system. Paper presented at the annual meeting of the American Association of Pharmaceutical Scientists, Denver, CO, October 2001.
31. Wang Z, Gorski JC, Hamman MA, Huang SM, Lesko LJ, Hall SD: The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther 2001;70:317-326.
32. Wang Z, Hamman MA, Huang SM, Lesko LJ, Hall SD: Effect of St John's wort on the pharmacokinetics of fexofenadine. Clin Pharmacol Ther 2002;71:414-420.
33. Hall SD, Wang Z, Huang SM, Hamman MA, Vasavada N, Adigun AQ, et al: The interaction between St John's wort and an oral contraceptive. Clin Pharmacol Ther 2003;74(6):525-535.
34. A catalog of FDA approved drug products. Retrieved from www.fda.gov/cder/approval/index.htm; pdrel.thomsonhc.com/pdrel/librarian
35. FTC warning. Retrieved from www.ftc.gov/opa/2001/06/cureall.htm
36. Budzinski JW, Foster BC, Vandenhoek S, Arnason JT: An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. Phytomedicine 2000;7:273-282.
37. Gorski JC, Huang S-M, Zaheer N, et al: The effect of echinacea on CYP3A activity in vivo. Clin Pharmacol Ther 2003;73:8.
38. Yin OQ, et al Tomlinson B, Chow MS: Prediction and mechanism of herb-drug interaction: effect of gingko biloba on omega zole in Chinese subjects. Paper presented at the annual meeting of the American Society of Clinical Pharmacology, Washington, DC, April 2003. Abstract in Clin Pharmacol Ther 2003;P94.
39. Chow MS: A pharmacokinetic-pharmacogenamic approach in studying herb-drug interaction. Paper presented at the annual meeting of the American College Clinical Pharmacology, Tampa, FL, September 22, 2003.
40. Lilja JJ, Kivisto KT, Neuvonen PJ: Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin. Clin Pharmacol Ther 1999;66(2):118-127.
41. Yee GC, Stanley DL, Pessa LJ, Dalla Costa T, Beltz SE, Ruiz J, et al: Effect of grapefruit juice on blood cyclosporin concentration. Lancet 1995;345(8955):955-956.
42. Lilja JJ, Kivisto KT, Neuvonen PJ: Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastatin. Clin Pharmacol Ther 2000;68(4):384-390.
43. Fuhr U, Maier-Bruggemann A, Blume H, Muck W, Unger S, Kuhlmann J, et al: Grapefruit juice increases oral nimodipine bioavailability. Int J Clin Pharmacol Ther 1998;36(3):126-132.
44. Lilja JJ, Kivisto KT, Backman JT, Neuvonen PJ: Effect of grapefruit juice dose on grapefruit juice-triazolam interaction: repeated consumption prolongs triazolam half-life. Eur J Clin Pharmacol 2000; 56(5):411-415.
45. Kupferschmidt HH, Fattinger KE, Ha HR, Follath F, Krahenbuhl S: Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man. Br J Clin Pharmacol 1998;45(4):355-359.
46. Lundahl J, Regardh CG, Edgar B, Johnsson G: Effects of grapefruit juice ingestion-pharmacokinetics and haemodynamics of intravenously and orally administered felodipine in healthy men. Eur J Clin Pharmacol 1997;52(2):139-145.
47. Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, et al: The cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice. Eur J Clin Pharmacol 1997;52(4):311-315.
48. Kupferschmidt HH, Ha HR, Ziegler WH, Meier PJ, Krahenbuhl S: Interaction between grapefruit juice and midazolam in humans. Clin Pharmacol Ther 1995;58(1):20-28.
49. Lilja JJ, Kivisto KT, Backman JT, Lamberg TS, Neuvonen PJ: Grapefruit juice substantially increases plasma concentrations of buspirone. Clin Pharmacol Ther 1998;64(6):655-660.
50. Kantola T, Kivisto KT, Neuvonen PJ: Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1998;63(4):397-402. Comment in Clin Pharmacol Ther 2000;67(6):690.
51. Kantola T, Kivisto KT, Neuvonen PJ: Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1998;63(4):397-402. Comment in Clin Pharmacol Ther 2000;67(6):690.
52. Gross AS, Goh YD, Addison RS, Shenfield GM: Influence of grapefruit juice on cisapride pharmacokinetics. Clin Pharmacol Ther 1999;65(4):395-401.
53. Huang S-M, Hall SD, Watkins P, Love LA, Serabjit-Singh C, Betz JM, et al: Drug interactions with herbal products & grapefruit juice: a conference report. Clin Pharmacol Ther, in press.
54. Piazza T, Huang S-M, Hepp P: FDA evaluation of drug grapefruit interaction labeling. Paper presented at the annual meeting of the American College of Clinical Pharmacology, San Francisco, September 2002, and at the FDA science forum, Washington, DC, April 2003.
55. Wei X, Park M, Ahn H: Analysis of grapefruit juice interactions with HMG Coa reducfase inhilators. Paper presented at the American Association of Pharmaceutical Scientists Fourth Annual Meeting and Exposition, New Orleans, LA, November 14, 1999.
56. Park MH, Marins R, Weix, Green M: Rhabdomyolysis associated with lovastatin and grapefruit juice interaction. Paper presented at the FDA Science Forum, Washington, DC, February 2000.
57. Malhotra S, Bailey DG, Palne MF, Watkins PB: Seville orange juice-felodipine interaction: comparison with dilute grapefruit juice and involvement of furocoumarins. Clin Pharmacol Ther 2001; 69(1):14-23.
58. Perloff MD, von Moltke LL, Greenblatt DJ: Fexofenadine transport in Caco-2 cells: inhibition with verapamil and ritonavir. J Clin Pharmacol 2002;42(11):1269-1274.
59. Wallace AW, Victory JM, Amsden GW: Lack of bioequivalence when levofloxacin and calcium-fortified orange juice are coadministered to healthy volunteers. J Clin Pharmacol 2003;43(5): 539-544.
60. Wallace AW, Victory JM, Amsden GW: Lack of bioequivalence of gatifloxacin when coadministered with calcium-fortified orange juice in healthy volunteers. J Clin Pharmacol 2003;43(1):92-96.
61. Neuhofel AL, Wilton JH, Victory JM, Hejmanowsk LG, Amsden GW: Lack of bioequivalence of ciprofloxacin when administered with calcium-fortified orange juice: a new twist on an old interaction. J Clin Pharmacol 2002;42:461-466.
62. Kontiokari T, Sundqvist K, Nuutinen M, Pokka T, Koskela M, Uhari M: Randomised trial of cranberry-lingonberry juice and Lactobacillus GG drink for the prevention of urinary tract infections in women. BMJ 2001;322(7302):1571.
63. British Committee on Safety of Medicines: Current problems in pharmacovigilance, September 2003. Retrieved from www.mca. gov.uk/ourwork/monitorsafequalmed/currentproblems/cpsept2003.pdf
64. Suvarna R, Pirmohamed M, Henderson L: Possible interaction between warfarin and cranberry juice. BMJ 2003;327:1454.
65. Makris, M, Maclean RM: Interaction between warfarin and cranberry juice. Premature conclusion? Rapid response to Suvarna et al [ref 63]. Retrieved from bmj.com
66. Gorski JC, Jones DR, Haehner-Daniels BD, Hamman MA, O'Mara EM Jr, Hall SD: The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin Pharmacol Ther 1998;64(2):133-143.
67. Fleishaker JC, Pearson LK, Peters GR; Gender does not affect the degree of induction of tirilazad clearance by phenobarbital. Eur J Clin Pharmacol 1996;50:139-145.
68. Hamelin BA, Bouayad A, Methot J, Jobin J, Desgagnes P, Poirier P, et al: Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity. Clin Pharmacol Ther 2000;67(5):466-477.
69. Brynne N, Forslund C, Hallen B, Gustafsson LL, Bertilsson L: Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity. Br J Clin Pharmacol 1999;48(4):564-572.
70. Leape LL, Bates DW, Cullen DJ, Cooper J, Demonaco HJ, Gallivan T, et al: Systems analysis of adverse drug events. ADE Prevention Study Group. JAMA 1995;274(1):35-43.
71. Greenblatt DJ, von Moltke LL, Harmatz JS, Chen G, Weemhoff JL, Jen C, et al: Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice. Clin Pharmacol Ther 2003;74(2):121-129.
72. Bhattaram VA, Graefe U, Kohlert C, Veit M, Derendorf H: Pharmacokinetics and bioavailability of herbal medicinal products. Phytomedicine 2002;9(suppl 3):1-33.
73. Burkhart GA, Sevka MJ, Temple R, Honig PK: Temporal decline in filling prescriptions for terfenadine closely in time with those for either ketoconazole or erythromycin. Clin Pharmacol Ther 1997; 61(1):93-96.
74. Smalley W, Shatin D, Wysowski DK, Gurwitz J, Andrade SE, Goodman M, et al: Contraindicated use of cisapride: impact of food and drug administration regulatory action. JAMA 2000;284(23):3036-3039. Comment in JAMA 2000;284(23):3047-3049.
75. Smalley W, Shatin D, Wysowski DK, Gurwitz J, Andrade SE, Goodman M, et al: Contraindicated use of cisapride: impact of food and drug administration regulatory action. JAMA 2000;284(23):3036-3039. Comment in JAMA 2000;284(23):3047-3049.
76. Juurlink DN, Mamdani M, Kopp A, Laupacis A, Redelmeier DA: Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA 2003;289(13):1652-1658.
77. Food and Drug Administration: Concept Paper: Premarketing Risk Assessment. Rockville, MD: Food and Drug Administration, 2003. Retrieved from www.fda.gov/cder/meeting/riskManageI.htm; www.fda.gov/cder/meeting/riskManageII.htm; www.fda.gov/cder/meeting/riskManageIII.htm
78. Roche letter. Retrieved from www.fda.gov/medwatch/safety/1998/posico2.htm